Broncus Holding

Broncus Holding FCF Yield

The Free Cash Flow Yield of Broncus Holding (2216.HK) as of Nov 4, 2026 is -8.83 %. In the previous year, Free Cash Flow Yield was -10.50 % — a change of -15.88% (higher).

FCF Yield

-8.83 %

YoY

-15.88%

Last updated:

Free Cash Flow Yield of Broncus Holding is 2025 -8.83 % . Free Cash Flow Yield of Broncus Holding was 2024 -10.50 % . It decreases by -15.88% higher compared to the previous year.

The Broncus Holding FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
-16.46 USD
Jan 1, 2020
-17.04 USD
Jan 1, 2021
-33.94 USD
Jan 1, 2022
-32.35 USD
Jan 1, 2023
-27.29 USD
Jan 1, 2024
-10.50 USD
Jan 1, 2025
-8.83 USD
The Broncus Holding FCF Yield history
YEARFCF YieldYoY
-8.83 %-15.88%
-10.50 %-61.53%
-27.29 %-15.64%
-32.35 %-4.69%
-33.94 %+99.11%
-17.04 %+3.56%
-16.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Broncus Holding Stock analysis

What does Broncus Holding do? Broncus Holding Corp generates revenue through the sale of medical device and consumable products across multiple therapeutic areas. The company's diagnostic solutions include FleXNeedle, ATV Sheath, and ATV Balloon, targeting healthcare providers for diagnostic procedures. Lung cancer treatment solutions feature InterVapor for lung cancer and H-Marker, sold to hospitals and oncology centers. Chronic obstructive pulmonary disease (COPD) solutions consist of InterVapor for COPD and TLD Ablation System, marketed to respiratory care facilities. Navigation platforms like Lungpoint, Lungpro, and New Generation Navigation Platform are supplied to medical institutions requiring advanced imaging guidance. The firm's product portfolio is structured around four key solution areas: diagnostics, lung cancer treatment, COPD management, and navigation systems. Diagnostic tools such as FleXNeedle and ATV products are used in minimally invasive procedures, while InterVapor serves dual purposes for both lung cancer and COPD applications. The TLD Ablation System is specifically designed for COPD treatment, and navigation platforms support precise procedural guidance in respiratory interventions. Broncus Holding Corp's primary customers are healthcare institutions including hospitals, specialized oncology centers, and respiratory care facilities. These entities purchase the company's medical devices and consumables for clinical use in treating respiratory conditions. The company's commercialization strategy focuses on direct sales to medical facilities rather than through third-party distributors, ensuring consistent product application and support. Broncus Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Broncus Holding stock

Free Cash Flow Yield of Broncus Holding is -8.83 % in 2025.

Free Cash Flow Yield of Broncus Holding changed from -10.50 % to -8.83 %, representing a -15.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Broncus Holding since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Broncus Holding with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Broncus Holding

All Key Metrics — Broncus Holding